What type of study is this?

December 8, 2025Blood

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

XLXiaofan LiDalian Ocean University

Discussion

Member takes

Implication

Retrospective analysis demonstrates reduced stem cell mobilization efficiency in patients treated with daratumumab, indicating G-CSF and etoposide may improve outcomes.

Key Points

Daratumumab impaired stem cell mobilization, leading to reduced CD34+ cell yields and more frequent apheresis.
Patients receiving etoposide plus G-CSF achieved optimal CD34+ cell collection rates comparable to those with lenalidomide.
Neutropenia duration was longer in patients treated with daratumumab, impacting recovery times post-ASCT.
Efficient stem cell mobilization strategies are crucial for improving transplant outcomes in multiple myeloma.

Cite This Study

Xiaofan Li (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc17 https://doi.org/10.1182/blood-2025-7694

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis demonstrates reduced stem cell mobilization efficiency in patients treated with daratumumab, indicating G-CSF and etoposide may improve outcomes.

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider